💊Licensing Opportunities for RXFP1 Agonists by NIH
The National Center for Advancing Translational Sciences (NCATS), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the licensing opportunities for the inventions listed below, which are owned by an agency of the U.S. Government, Florida International University (FIU), and University of South Florida (USF). The NCATS has taken the lead in both patenting and licensing via consolidation of rights under an Inter Institutional Agreement (IIA). The inventions are available for licensing and collaboration to achieve expeditious commercialization results of federally funded research and development.
Learn More💊FDA Notice on CAMZYOS Patent Extension and Review Period
The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 29, 2024. After review of the calculation of the applicable regulatory review period of the biologic product CAMZYOS (U.S. patent numbers 9,181,200; 9,585,883) in that notice, FDA has determined that a revision of the supplementary information section is warranted. This notice corrects the applicable regulatory review period language.
Learn More🦟EPA Notice
The Environmental Protection Agency (EPA or "Agency") is announcing the availability of and soliciting public comment on materials that are being submitted to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) Scientific Advisory Panel (SAP) for peer review on "Determining the Absence of Novel Proteins in the Saliva of Genetically Engineered Mosquitoes for Mosquito Control." The white paper, charge questions, background documents, and related supporting materials are available for public review and comment. The FIFRA SAP will consider and review the documents at a 3-day virtual public meeting that was previously announced in the Federal Register of July 24, 2025. The virtual public meeting will be held on November 3-5, 2025, via a webcast platform such as "Zoomgov.com" and audio teleconference.
Learn More🌱APHIS Withdraws EIS Notices for Genetically Engineered Organisms
This notice advises the public that the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture (USDA) is withdrawing notices of intent to prepare environmental impact statements for two petitions seeking determinations of nonregulated status for organisms developed using genetic engineering. APHIS' decision to withdraw the notices of intent is consistent with APHIS' July 9, 2025 Program Update that as of that date, APHIS will no longer prepare an analysis under the National Environmental Policy Act to accompany its review of petitions seeking a determination of nonregulated status. This document provides public notice of this withdrawal.
Learn More🏥NIH Closed Meeting Notices for Grant Evaluations and Proposals
The Department of Health and Human Services announces closed meetings of the Center for Scientific Review to evaluate grant applications and contract proposals in scientific research. These meetings will occur virtually and focus on various health-related topics, emphasizing the careful review of confidential information associated with grant applications.
Learn More💊FDA Notice on Patent Extension for KISUNLA Regulatory Review
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KISUNLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More🧪Notice of NIH Closed Meetings for Grant Evaluations
The Department of Health and Human Services announces closed meetings of the Center for Scientific Review to evaluate grant applications related to various health and research topics. The meetings, held virtually, involve several committees dedicated to assessing the potential of submitted proposals in addressing key scientific challenges.
Learn More🌽Bayer CropScience Seeks Nonregulated Status for MON 95275 Maize
We are advising the public that the Animal and Plant Health Inspection Service has received a petition from Bayer CropScience seeking a determination of nonregulated status for MON 95275 maize (corn) which has been developed using genetic engineering to produce two insecticidal proteins and a double-stranded RNA transcript to provide protection from feeding damage caused by targeted coleopteran (corn rootworm) insect pests. We are making the petition and draft plant pest risk assessment available for public review and comment.
Learn More🧬Government-Owned Inventions Available for Licensing
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Learn More🦠Exclusive License Opportunity for Engineered Commensal Bacteria Technology
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Inter- Institutional Agreement-Institution Lead to CZ Biohub SF, LLC ("CZB"), located in San Francisco, California, in its rights to the technologies and patent applications listed in the Supplementary Information section of this notice.
Learn More